MITOTOX

Drug

D1407 | Carnitine

Molecular Formula	C7H15NO3
Molecular Weight	161.2
Structure
State	solid
Clearance	Total body clearance was found to be a mean of 4L/h.
Volume of distribution	The steady state volume of distribution (Vss) of an intravenously administered dose, above endogenous baseline levels, was calculated to be 29.0 +/- 7.1L. However this value is predicted to be an underestimate of the true Vss.
Route of elimination	Following a single intravenous dose, 73.1 +/- 16% of the dose was excreted in the urine during the 0-24 hour interval. Post administration of oral carnitine supplements, in addition to a high carnitine diet, 58-65% of the administered radioactive dose was recovered from urine and feces in 5-11 days.
Protein binding	None
Half life	17.4 hours (elimination) following a single intravenous dose.
Absorption	Absolute bioavailability is 15% (tablets or solution). Time to maximum plasma concentration was found to be 3.3 hours.
Description	quaternary ammonium compound involved in metabolism

A16AA01 Levocarnitine

[A16AA] Amino acids and derivatives

[A16A] OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS

[A16] OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS

[A] Alimentary tract and metabolism

Toxicity	Dose	Time	Species	Model	Method	Action	Positive criterion	Reference
MITOCHONDRIAL FATTY ACID BETA OXIDATION	0.5mM	24hr		U-937, MCF-7, and T47D	quantifies the conversion of [9,10-3H(N)]-palmitic acid to 3H2O with diffusion	stimulate		273

Organism	Test type	Route	Dose (normalized dose)	Source
rat	LD50	subcutaneous	13500mg/kg (13500mg/kg)	Acta Biologica et Medica Germanica. Vol. 3, Pg. 28, 1959.
mouse	LD50	intravenous	610mg/kg (610mg/kg)	British UK Patent Application. Vol. #2008578,
rat	LD50	intravenous	995mg/kg (995mg/kg)	British UK Patent Application. Vol. #2008578,
mouse	LD50	subcutaneous	11500mg/kg (11500mg/kg)	Acta Biologica et Medica Germanica. Vol. 3, Pg. 28, 1959.

beta-hydroxy-gamma-N-trimethylaminobutyric acid, 3-hydroxy-4-N,N,N-trimethylaminobutyrate